EW - Edwards Lifesciences Commits to Fair Competition Amid Regulatory Scrutiny Analyst Upgrades Stock | Benzinga
The European Commission conducted a surprise inspection at Edwards Lifesciences Corp's (NYSE: EW) facility within a European Union member state due to suspicions of potential market power abuse, possibly infringing upon the EU's antitrust regulations.
Edwards Lifesciences, a player in the global production of medical equipment for structural heart ailments, expressed its steadfast dedication to promoting fair and competitive practices in the industry.
"Edwards Lifesciences is cooperating with the European Commission regarding its inspection in relation to EU competition law," the company said in a statement to Reuters.
With the scrutiny undergoing, Oppenheimer upgraded Edwards Lifesciences' stock to Outperform ...